Glycolytic Inhibitors Potentiated the Activity of Paclitaxel and Their Nanoencapsulation Increased Their Delivery in a Lung Cancer Model
Antiglycolytic agents inhibit cell metabolism and modify the tumor’s microenvironment, affecting chemotherapy resistance mechanisms. In this work, we studied the effect of the glycolytic inhibitors 3-bromopyruvate (3BP), dichloroacetate (DCA) and 2-deoxyglucose (2DG) on cancer cell properties and on...
Main Authors: | Andrea Cunha, Ana Catarina Rocha, Flávia Barbosa, Ana Baião, Patrícia Silva, Bruno Sarmento, Odília Queirós |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/10/2021 |
Similar Items
-
Sodium Dichloroacetate and 3-Bromopyruvate induce loss of cell viability and metabolic alterations in melanoma and breast cancer cells
by: Ana Catarina Rocha, et al.
Published: (2022-04-01) -
Inhibition of glycolysis disrupts cellular antioxidant defense and sensitizes HepG2 cells to doxorubicin treatment
by: Agnieszka Korga, et al.
Published: (2019-05-01) -
Inhibition of Key Glycolytic Enzyme Hexokinase 2 Ameliorates Psoriasiform Inflammation in vitro and in vivo
by: Zhuang L, et al.
Published: (2023-11-01) -
Glycolytic inhibitor 2-deoxyglucose simultaneously targets cancer and endothelial cells to suppress neuroblastoma growth in mice
by: Chao-Cheng Huang, et al.
Published: (2015-10-01) -
In-vivo magnetic resonance spectroscopy of lactate as a non-invasive biomarker of dichloroacetate activity in cancer and non-cancer central nervous system disorders
by: David O. Kamson, et al.
Published: (2023-03-01)